In the initial Phase III study , hemo - or peritoneal dialysis patients with hyperphosphatemia were randomized @:@ to receive sucroferric oxyhydroxide @-@ @ g/day ( @-@ tablets/day ; n = @ ) or sevelamer @-@ @ g/day ( @-@ tablets/day ; n = @ ) for @ weeks .